Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry
European Journal of Nuclear Medicine and Molecular Imaging · 2026-10 · 53 (12) · 6849-6857
DOI: 10.1007/s00259-026-08030-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 26.06.2026. Verfasst von Sophie Carina Siegmund und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, Munich, 81377, Germany. sophie.siegmund@med.uni…. Hauptthemen laut MEDLINE: Metformin, Kidney, Prostatic Neoplasms, Antigens, Surface. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Munich Clinician Scientist Program.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, Munich, 81377, Germany. sophie.siegmund@med.uni-muenchen.de.
- Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Marchioninistr. 15, Munich, 81377, Germany.
- Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
- Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET- KUM, ENETS Certified Center of Excellence), LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
- Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California Los Angeles UCLA, Los Angeles, CA, USA.
Förderung
- Munich Clinician Scientist Program
Zitieren
APA
Siegmund, S. C., Delker, A., Widjaja, L., Hornfeck, J., Wu, M., Unterrainer, L. M., Gildehaus, F. J., Böning, G., Werner, R. A., & Ells, Z. (2026). Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 53(12), 6849-6857. https://doi.org/10.1007/s00259-026-08030-x
Vancouver
Siegmund SC, Delker A, Widjaja L, Hornfeck J, Wu M, Unterrainer LM, et al. Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(12):6849-6857. doi:10.1007/s00259-026-08030-x
BibTeX
@article{Siegmund2026,
author = {Siegmund, Sophie Carina and Delker, Astrid and Widjaja, Liam and Hornfeck, Johannes and Wu, Muyu and Unterrainer, Lena M and Gildehaus, Franz Josef and Böning, Guido and Werner, Rudolf A and Ells, Zachary},
title = {Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {12},
pages = {6849--6857},
doi = {10.1007/s00259-026-08030-x}
}
EUVIMED